SBI Securities Co. Ltd. Invests $60,000 in Vir Biotechnology, Inc. (NASDAQ:VIR)

SBI Securities Co. Ltd. purchased a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 8,222 shares of the company’s stock, valued at approximately $60,000.

Other large investors have also recently bought and sold shares of the company. KBC Group NV lifted its stake in shares of Vir Biotechnology by 136.5% in the fourth quarter. KBC Group NV now owns 8,970 shares of the company’s stock valued at $66,000 after purchasing an additional 5,177 shares during the period. CIBC Asset Management Inc acquired a new position in Vir Biotechnology in the 4th quarter valued at about $74,000. Captrust Financial Advisors purchased a new position in shares of Vir Biotechnology during the third quarter valued at approximately $118,000. Quarry LP lifted its stake in shares of Vir Biotechnology by 901.8% during the 3rd quarter. Quarry LP now owns 17,000 shares of the company’s stock worth $127,000 after purchasing an additional 15,303 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in shares of Vir Biotechnology during the third quarter worth $138,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Insider Buying and Selling

In other Vir Biotechnology news, Director George A. Scangos sold 10,964 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the transaction, the director now directly owns 708,295 shares of the company’s stock, valued at $6,948,373.95. This represents a 1.52 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Verneuil Vanina De sold 7,373 shares of the firm’s stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the sale, the executive vice president now directly owns 79,460 shares of the company’s stock, valued at $726,264.40. The trade was a 8.49 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,859 shares of company stock valued at $326,458. Corporate insiders own 15.60% of the company’s stock.

Vir Biotechnology Stock Down 7.4 %

Vir Biotechnology stock opened at $7.37 on Tuesday. The firm has a fifty day moving average of $9.53 and a 200-day moving average of $8.47. Vir Biotechnology, Inc. has a 52-week low of $6.56 and a 52-week high of $14.45. The firm has a market capitalization of $1.01 billion, a P/E ratio of -1.88 and a beta of 1.17.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The company had revenue of $12.37 million for the quarter, compared to analyst estimates of $8.14 million. On average, research analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, February 28th. JPMorgan Chase & Co. raised their target price on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research report on Thursday, January 9th. Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. Finally, Barclays lifted their price target on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a report on Friday, February 28th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.67.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).